The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction: A Randomized Trial
Abstract
CONTEXT: Bare-metal stenting with abciximab pretreatment is currently considered a reasonable reperfusion strategy for acute ST-segment elevation myocardial infarction (STEMI). Sirolimus-eluting stents significantly reduce the need for target-vessel revascularization (TVR) vs bare-metal stents but substantially increase procedural costs. At current European list prices, the use of tirofiban instead of abciximab would absorb the difference in cost between stenting with sirolimus-eluting vs bare-metal stents. OBJECTIVE: To evaluate the clinical and angiographic impact of single high-dose bolus tirofiban plus sirolimus-eluting stenting vs abciximab plus bare-metal stenting in patients with STEMI. DESIGN, SETTING, AND PATIENTS: Prospective, single-blind, randomized controlled study (Single High Dose Bolus Tirofiban and Sirolimus Eluting Stent vs Abciximab and Bare Metal Stent in Myocardial Infarction [STRATEGY]) of 175 patients (median age, 63 [interquartile range, 55-72] years) presenting to a single referral center in Italy with STEMI or presumed new left bundle-branch block and randomized between March 6, 2003, and April 23, 2004. INTERVENTION: Single high-dose bolus tirofiban regimen plus sirolimus-eluting stenting (n = 87) vs standard-dose abciximab plus bare-metal stenting (n = 88). MAIN OUTCOME MEASURES: The primary end point was a composite of death, nonfatal myocardial infarction, stroke, or binary restenosis at 8 months. Secondary outcomes included freedom, at day 30 and month 8, from major cardiac or cerebrovascular adverse events (composite of death, reinfarction, stroke, and repeat TVR). RESULTS: Cumulatively, 14 of 74 patients (19%; 95% confidence interval [CI], 10%-28%) in the tirofiban plus sirolimus-eluting stent group and 37 of 74 patients (50%; 95% CI, 44%-56%) in the abciximab plus bare-metal stent group reached the primary end point (hazard ratio, 0.33; 95% CI, 0.18-0.60; P<.001 [P<.001 by Fischer exact test]). The cumulative incidence of death, reinfarction, stroke, or TVR was significantly lower in the tirofiban plus sirolimus-eluting stent group (18%) vs the abciximab plus bare-metal stent group (32%) (hazard ratio, 0.53; 95% CI, 0.28-0.92; P = .04), predominantly reflecting a reduction in the need for TVR. Binary restenosis was present in 6 of 67 (9%; 95% CI, 2%-16%) and 24 of 66 (36%; 95% CI, 26%-46%) patients in the tirofiban plus sirolimus-eluting stent and abciximab plus bare-metal stent groups, respectively (P = .002). CONCLUSION: Tirofiban-supported sirolimus-eluting stenting of infarcted arteries holds promise for improving outcomes while limiting health care expenditure in patients with myocardial infarction undergoing primary intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Moses, J. W., Leon, M. B., Popma, J. J., Fitzgerald, P. J., Holmes, D. R., O'Shaughnessy, C., Caputo, R. P., Kereiakes, D. J., Williams, D. O., Teirstein, P. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035071 · Cited by 4,224
Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy
McFadden, E. P., Stabile, E., Regar, E., Cheneau, E., Ong, A. T., Kinnaird, T., Suddath, W. O., Weissman, N. J., Torguson, R., Kent, K. M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17275-9 · Cited by 1,436
Self-citationComparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction
Stone, G. W., Grines, C. L., Cox, D. A., Garcia, E., Tcheng, J. E., Griffin, J. J., Guagliumi, G., Stuckey, T., Turco, M., Carroll, J. D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013404 · Cited by 1,277
Platelet Glycoprotein IIb/IIIa Inhibition with Coronary Stenting for Acute Myocardial Infarction
Montalescot, G., Barragan, P., Wittenberg, O., Ecollan, P., Elhadad, S., Villain, P., Boulenc, J.-M., Morice, M.-C., Maillard, L., Pansiéri, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106213442503 · Cited by 1,186
Rao, A. K., Pratt, C., Berke, A., Jaffe, A., Ockene, I., Schreiber, T. L., Bell, W. R., Knatterud, G., Robertson, T. L., & Terrin, M. L. (1988) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(88)90158-1 · Cited by 979
Coronary Angioplasty with or without Stent Implantation for Acute Myocardial Infarction
Grines, C. L., Cox, D. A., Stone, G. W., Garcia, E., Mattos, L. A., Giambartolomei, A., Brodie, B. R., Madonna, O., Eijgelshoven, M., Lansky, A. J., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912233412601 · Cited by 946
Topol, E. J., Moliterno, D. J., Herrmann, H. C., Powers, E. R., Grines, C. L., Cohen, D. J., Cohen, E. A., Bertrand, M., Neumann, F.-J., Stone, G. W., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106213442502 · Cited by 677
Lemos, P. A., Serruys, P. W., van Domburg, R. T., Saia, F., Arampatzis, C. A., Hoye, A., Degertekin, M., Tanabe, K., Daemen, J., Liu, T. K. K., et al. (2004) · Circulation · doi:10.1161/01.cir.0000109138.84579.fa · Cited by 543
Self-citationFuster, V., Smith, S. C., Alpert, J. S., Hochman, J. S., Lamas, G. A., Halperin, J. L., Antman, E. M., Bates, E., Armstrong, P. W., Mullany, C. J., et al. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/5fwy-yt51 · Cited by 340
Cited by
Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents
Kastrati, A., Mehilli, J., Pache, J., Kaiser, C., Valgimigli, M., Kelbæk, H., Menichelli, M., Sabaté, M., Suttorp, M. J., Baumgart, D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067484 · Cited by 1,006
Self-citationSpertus, J. A., Kettelkamp, R., Vance, C., Decker, C., Jones, P. G., Rumsfeld, J. S., Messenger, J. C., Khanal, S., Peterson, E. D., Bach, R. G., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.618066 · Cited by 854
A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes
Mehran, R., Pocock, S. J., Nikolsky, E., Clayton, T., Dangas, G. D., Kirtane, A. J., Parise, H., Fahy, M., Manoukian, S. V., Feit, F., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.09.076 · Cited by 684
White, H. D., & Chew, D. P. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61237-4 · Cited by 588
Bangalore, S., Kumar, S., Fusaro, M., Amoroso, N., Attubato, M. J., Feit, F., Bhatt, D. L., & Slater, J. (2012) · Circulation · doi:10.1161/circulationaha.112.097014 · Cited by 574
Metadata
- Authors
- Valgimigli, M., Percoco, G., Malagutti, P., Campo, G., Ferrari, F., Barbieri, D., Cicchitelli, G., McFadden, E. P., Merlini, F., Ansani, L., Guardigli, G., Bettini, A., Parrinello, G., Boersma, E., Ferrari, R., & STRATEGY Investigators, F. T.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2005-05-04
- Volume
- 293
- Issue
- 17
- Pages
- 2109
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2121785565
- Cited by
- 307
- References
- 19
- FWCI
- 39.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction: A Randomized Trial. https://app.cochat.ai/papers/10.1001/jama.293.17.2109
- The paper
- Valgimigli, M., Percoco, G., Malagutti, P., Campo, G., Ferrari, F., Barbieri, D., Cicchitelli, G., McFadden, E. P., Merlini, F., Ansani, L., Guardigli, G., Bettini, A., Parrinello, G., Boersma, E., Ferrari, R., & STRATEGY Investigators, F. T. (2005). Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction: A Randomized Trial. JAMA. https://doi.org/10.1001/jama.293.17.2109
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.